EGYPT – Minapharm Pharmaceuticals and Sanofi have struck an exclusive manufacturing and supply agreement for the localization of the full range of Sanofi’s flagship market leader product, Clexane.

As specified in the exclusive manufacturing and supply agreement, Sanofi and Minapharm are working closely to meet the anticipated strong future demand for Clexane.

In a joint statement, Dr. Ahmed Raouf, Managing Director and Chairperson of Sanofi Egypt, said: “This agreement affirms Sanofi Egypt’s pledge to support the localization plan of pharmaceutical and biological industries in Egypt.”

Dr. Ahmed Raouf explained that Sanofi Egypt continues to support the Egyptian national localization plan by facilitating the transfer of advanced manufacturing technology in cooperation with distinctive industry partners.

Notably, Sanofi Egypt is an affiliate of Sanofi, a global healthcare leader with more than 100,000 employees in 100 countries.

The strategic agreement between Sanofi and Minapharm aligns with the specific goals within Egypt’s national localization strategy of biopharmaceutical manufacturing.

Moreover, this groundbreaking move towards localizing the manufacturing of Sanofi’s Clexane adapts to changing market dynamics and enhancement of industrial innovative technologies.

“This agreement signifies a continuation of efforts to provide essential and modern treatments to the Egyptian patient,” underscored Dr. Ahmed Raouf.

The signing ceremony was presided over by Dr. Ahmed Raouf, Managing Director and Chairperson on behalf of Sanofi Egypt, and Dr. Wafik Bardissi, Chairman and Chief Executive Officer of Minapharm on behalf of Minapharm.

The agreement was signed in the presence of Sanofi Senior Management, including Christelle Saghbini, Head of Innovate to Grow Markets, Jeremy Goldnadel, Cluster Head of International General Medicine, and Ahmed Youssef, Head of Manufacturing site.

Commenting on the collaboration with Sanofi, Dr. Wafik Bardissi, Chairman and CEO of Minapharm said: “This partnership with Sanofi corroborates the common national health policy directives with the commitment of both parties to ensure elevated patient access to essential complex biologics.”

Dr. Wafik Bardissi further said that the alliance complements the local, regional, and global technology contribution of Minapharm and its European subsidiaries to the world’s bio-industry.

Through the newly forged pact, the manufacturing of Clexane will take place in Minapharm’s second new state-of-the-art biopharmaceutical facility in Egypt.

It is important to note that Minapharm’s new facility in Egypt is dedicated to diverse research, development, and manufacture of complex bioengineered proteins.

In related news, Minapharm, SaudiVax, and MiGenTra GmbH entered into a Memorandum of Understanding for the companies to jointly pursue potential business opportunities in Saudi Arabia and the Gulf Cooperation Countries.

This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in the Kingdom of Saudi Arabia.

Leveraging their strengths, the three parties are committed to advancing healthcare solutions and meeting the growing demand for high-quality biologics in the Region.

The partnership intends to match Minapharm’s and MiGenTra’s cutting-edge development and manufacturing tech and translational experience of quality, affordable bio-engineered products with SaudiVax’s industrial capabilities and commercial reach in the Gulf region.

With wholly owned subsidiaries in Cairo and Berlin, Minapharm is one of the leading pharmaceutical companies in Egypt and the Middle East.

The premier biopharmaceutical company commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex genetically engineered proteins.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.